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Abstract
Background: Trial oversight is important for trial governance and conduct. Patients and/or lay members of the
public are increasingly included in trial oversight committees, influenced by international patient and public
involvement (PPI) initiatives to improve the quality and relevance of research. However, there is a lack of guidance
on how to undertake PPI in trial oversight and tokenistic PPI remains an issue. This paper explores how PPI
functions in existing trial oversight committees and provides recommendations to optimise PPI in future trials. This
was part of a larger study investigating the role and function of oversight committees in trials facing challenges.
Methods: Using an ethnographic study design, we observed oversight meetings of eight UK trials and conducted
semi-structured interviews with members of their trial steering committees (TSCs) and trial management groups
(TMGs) including public contributors, trial sponsors and funders. Thematic analysis of data was undertaken, with
findings integrated to provide a multi-perspective account of how PPI functions in trial oversight.
Results: Eight TSC and six TMG meetings from eight trials were observed, and 66 semi-structured interviews
conducted with 52 purposively sampled oversight group members, including three public contributors. PPI was
reported as beneficial in trial oversight, with public members contributing a patient voice and fulfilling a patient
advocacy role. However, public contributors were not always active at oversight meetings and were sometimes felt
to have a tokenistic role, with trialists reporting a lack of understanding of how to undertake PPI in trial oversight.
To optimise PPI in trial oversight, the following areas were highlighted: the importance of planning effective
strategies to recruit public contributors; considering the level of oversight and stage(s) of trial to include PPI;
support for public contributors by the trial team between and during oversight meetings.
Conclusions: We present evidence-based recommendations to inform future PPI in trial oversight. Consideration
should be given at trial design stage on how to recruit and involve public contributors within trial oversight, as well
as support and mentorship for both public contributors and trialists (in how to undertake PPI effectively). Findings
from this study further strengthen the evidence base on facilitating meaningful PPI within clinical trials.
Keywords: Public involvement, User involvement, Patient involvement, Randomised trials, Trial steering committees,
Trial management groups, Trial monitoring, Trial oversight
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Introduction
Robust clinical trial oversight helps to safeguard partici-
pants by ensuring that trial conduct is in accordance with
international Good Clinical Practice guidelines, and trial
results are accurately reported [1, 2]. The UK Medical Re-
search Council (MRC) distinguishes between three levels
of trial oversight: the trial steering committee (TSC),
which provides overall supervision for the trial and is
comprised of an independent Chair and a majority of in-
dependent members; the independent data monitoring
committee (iDMC) responsible for considering emerging
trial data in relation to participant safety; and the trial
management group (TMG), comprised of the trial team
which facilitates the day-to-day running of the trial [3].
Lay members of the public or patients with a relevant
clinical condition are being included more frequently in
TSCs and TMGs [4, 5], based on the recognition of the
potential benefits of involving patients and the public in
healthcare research [6–9]. Incorporating the priorities of
healthcare users into research has the potential to im-
prove the relevance of research and reduce research
“waste” [9, 10]. There is also a moral imperative to pa-
tient and public involvement (PPI) in research based on
the belief that healthcare users should be involved in de-
cisions about research and healthcare that will affect
them [11]. The National Institute for Health Research
(NIHR) National Standards for Public Involvement high-
light the importance of involving the public in research
governance and leadership to ensure “decisions promote
and protect the public interest” [12]. Both the MRC and
the NIHR, two major funders of UK clinical trials, rec-
ommend that TSCs include patient or public member(s),
although no such guidance exists for TMGs [3, 13]. PPI
can occur from initial idea development through to dis-
semination of trial results [14–16] and can be especially
beneficial for shaping trial design and the selection of
outcomes relevant to patients [8, 17]. PPI has also been
reported to improve the recruitment of participants into
trials [18]. However, not all researchers are clear about
the benefits of PPI, and the risk of tokenistic PPI or lack
of meaningful partnership is a problem [5, 19–24].
Previous research has highlighted a lack of clarity and
guidance about the role and impact of PPI in trial over-
sight [4, 5, 25, 26] and conduct [20]. A previous qualita-
tive study found the inclusion of public contributors on
TMGs rather than TSCs was perceived as more useful as
the TMG meet more frequently and offer more oppor-
tunities for involvement [5]. However, a limitation of
this study was the reliance on retrospective interviews,
which are subject to recall bias, and trials were funded
some time ago (2006–2010) which does not reflect re-
cent emphasis on co-production and the involvement of
PPI [4]. Limited qualitative research investigating the im-
pact of PPI have not focused on trials specifically [27],
been limited to a single trials unit [28], or limited to one
type of trial (surgical trials) [22], and none have used an
ethnographic approach to observe actual PPI contribu-
tions. Non-participant observation combined with inter-
views offers the opportunity for a more detailed
understanding of how PPI actually functions within trials
[5, 27]. This paper aims to (1) describe how PPI functions
in trial oversight, using multiple qualitative methods, and
(2) contribute to recommendations for maximising PPI in
clinical trials, in collaboration with public contributors
with experience of involvement in trial oversight.
Methods
Data presented were collected within a larger ethno-
graphic study of the role and function of trial oversight
committees and their contribution to trial conduct in
trials facing challenges [29, 30]. We used a cross-
sectional ethnographic study design, including a combin-
ation of non-participant observation of TSC and TMG
meetings, and interviews with members of these com-
mittees and other key informants related to trial over-
sight. The methods have been reported in detail
previously [29, 30] and are summarised here.
Sampling
Data were collected between March 2013 and January
2014 from eight phase III UK trials identified as facing
challenges (e.g. recruitment problems, protocol deviation
or amendments). Trials were purposively sampled to
represent a range of clinical topics, healthcare settings
and type of intervention. Personnel from within these
trials were also purposively selected to include differing
roles and perspectives and included TSC and TMG
Chairs, Chief Investigators (CIs), trial team members,
trial sponsors, independent TSC members and patient
or public contributors (henceforth referred to as ‘public
contributors’). Additional key informants from outside
the eight trials were also interviewed, including trial fun-
ders, a sponsor and senior researchers with experience
of other challenging trials. Data collection and sampling
continued until data saturation was reached (no new
themes emerged during data analysis) [31].
Data collection
For each trial, one TSC meeting and one TMG meeting
in the study period were targeted for observation by the
researcher. Detailed field notes were taken during and
after the meetings, guided by an observation schedule
[30]. Semi-structured interviews were conducted either
face-to-face or by telephone, before or after the observed
meetings, according to participant availability and pref-
erence. Topic guides were developed and used to guide
interviews and included questions relating to PPI
(Table 1) [29].
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Written informed consent was provided by all com-
mittee members and interview participants, in advance
of each observation or interview. All observations and
interviews were undertaken by one qualitative researcher
(AD) and recorded and transcribed verbatim.
Data analysis
Thematic analysis was used to identify themes in the ob-
servational data (meeting transcripts and field notes) and
interview transcripts, using a mixture of inductive and
deductive coding and techniques of constant comparison
[32, 33], as previously described [29]. Data analysis was
conducted alongside data collection to allow emergent
themes to inform subsequent data collection. Coding
was conducted by AD, with a subset of interview and
meeting transcripts coded by other study members [29].
NVivo 10 [34] was used to aid organisation and refine-
ment of codes. To inform this paper, a second stage of
more fine-grained coding on data related to PPI was
conducted by a second qualitative researcher (AN) after
familiarisation with the dataset. Mind maps were used to
aid conceptualisation and organisation, then codes were
developed into broader categories and higher-level
themes, which were discussed and agreed with AD, JAL,
AS and KC. Finally, a descriptive account was written in-
tegrating both observational and interview data (KC,
AN). Data was triangulated to explore areas of diver-
gence and convergence in the two datasets, and the dif-
ferent participant perspectives represented.
Data presented have been anonymised to protect con-
fidentiality. Quotes from interviews are labelled with
participant ID and trial number. Observational data
from meeting recordings and observation notes are la-
belled according to the type of meeting and trial
number. Findings are reported using the Standards for
Reporting Qualitative Research (SPQR) Checklist [35]
(Supplementary table 1), and the GRIPP2 short-form
checklist for reporting PPI in research (Supplementary
table 2) [36].
Methods used for PPI within the study
Two public contributors with experience of involvement
in trial oversight committees (MEP and GT) were in-
vited by JAL to contribute to the writing of this paper.
Both accepted. Public contributors were not involved in
the design of this study.
Results
PPI representation in eight trials facing challenges
Overall, 14 meetings (eight TSC, six TMG) were ob-
served from the eight trials (Table 2), with details of re-
sponse rates reported previously [29].
Linked to these eight trials, 66 interviews were con-
ducted with 52 individuals, including TSC and TMG
members, three public contributors and other relevant
informants (Table 3).
Thirty-eight of the 52 participants discussed PPI across
43 interviews. Seven public contributors were present
across three TSC and three TMG meetings within four
of the eight trials (Table 2, trials 5–8). No public con-
tributors were at observed meetings for the other four
trials (trials 1–4), although interviewees reported that
TMG membership included public contributors in two
of these trials (1 and 2). In trial 3, interviewees described
how a public member had contributed strongly at the
trial start, but this had declined due to time commit-
ments and they were actively trying to recruit a new
member; there was brief discussion at the TMG meeting
about obtaining public representation. For trial 4, an
interviewee reported that a patient charity representative
was invited to TSCs, but their attendance had been poor.
The three public contributors interviewed were long-
standing members of their respective groups (2 TMG, 1
TSC), had some experience of the disease/condition
under study and/or experience of participating in previ-
ous oversight committees or patient advocacy groups.
All had current or previous professional careers, two
within an academic environment.
Eight themes relating to PPI in trial oversight were
identified across two broader topics. Two themes relate
to the role of PPI: (1) patient voice and advocacy and (2)
extent of PPI role. Six themes describe barriers and facil-
itators to meaningful PPI in trial oversight: (1) confusion
about definition and roles of PPI, (2) appreciated qual-
ities of public contributors, (3) routes to invite public
contributors, (4) involving PPI at the optimal level of
oversight and trial stage, (5) formality of oversight
Table 1 Patient and Public Involvement related questioning
within interviews*
Questioning for trialists/funder representatives/sponsor
representatives
Views of PPI and actual impact on trial conduct decisions
Role of PPI on the TMG/TSC
Background of public members on the TMG/TSC
Reasons for selecting public members to be part of the TMG/TSC
Views on which committee (TMG/TSC) public members are best
placed to contribute
Questioning for public contributors
Experience in trial oversight committees
Their understanding of their role in the committee
Examples of how they perceived they had influenced trial conduct
How they felt during oversight meetings
PPI patient and public involvement, TMG trial management group, TSC trial
steering committee
*Extracted from interview topic guides
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meetings and technical language and (6) support and/or
mentorship from the trial team.
The role of PPI in trial oversight
Patient voice and advocacy
Trialists commonly referred to the role of public con-
tributors in trial oversight as providing the patient per-
spective or voice, including patient advocacy. Public
contributors were perceived as enabling the oversight
committee to gain insight into participants’ experiences,
views and preferences regarding the clinical condition
and trial. They were also valued by trialists for their
practical contributions, for example commenting on
written documentation for trial participants. Patient ad-
vocacy included enabling links with appropriate patient
networks and acting as a spokesperson in research set-
tings outside of trial oversight, such as conferences or
meetings.
…the reason why they [public contributor] were in-
vited was so we got their views on how a patient
would feel … [what they] might be going through,
why patients might not want to participate in trials,
and how … they think a [specialist clinician] should
be approaching patients and sensitive issues. [07,
Trial manager, trial 1]
The public contributors interviewed generally shared
these perspectives, seeing their role as involving “quality
control” and/or safeguarding to ensure the trial is con-
ducted in a way that takes account of patients’ interests,
does not cause harm, and produces outcomes that will
benefit patients now and in the future.
My actual role, as I see it, is to represent the pa-
tients … to make sure their interests are dealt with
correctly, that they are not just used as pawns in the
research … as a piece of research data. At the end
of it, it is a patient...a person that they are talking
about, not just a source of data they can stick a tack
on or switch on. [35, public contributor, trial 7]
However, a dissenting view was expressed by one pub-
lic contributor, who felt that the advocacy role was bet-
ter served by clinicians who can understand complex
mechanisms underpinning a condition.
The idea of patient involvement in this [trial] seems
to stem from the fact that they thought that maybe
the doctors … would have their own ideals on what
should be examined, which may not necessarily be
that which benefits the patient the most. I don’t
think the patient representatives are in a terribly
strong position to be able to judge what does benefit
the patients most in practical terms … the patients
simply don’t know enough … understanding all the
mechanism, it’s a very highly complex thing [43b,
public contributor, trial 8]
Extent of PPI role
During meetings, public contributors were observed to
contribute to discussions about recruitment issues and
methods to improve the collection of patient-reported
outcomes (observation notes, trial 8 TMG and TSC).
Trial manager, trial 8 TSC: …the trial is very
dependent on questionnaires and quality of life





Meetings observed Public contributors
at meeting
Discussion of PPI if no contributors
at meeting observed
PPI in the trial reported by interviewees,
if not observed
TSC TMG TSC TMG TSC TMG
1 Oncology ✓ ✓ 0 0 x x On TMG, although not at meeting observed
2 Oncology ✓ x 0 – x – On TMG.
3 Arthritis ✓ ✓ 0 0 x ✓ Previous involvement of a public member,
trying to recruit a new member
4 Frailty ✓ ✓ 0 0 x ✓ Confusion as to whether certain trial
interactions with patients counted as
PPI. Patient charity representative
invited to TSC meetings with poor
attendance.
5 Oncology ✓ ✓ 0 2 x n/a
6 Urology ✓ x 1 – n/a –
7 Psychology ✓ ✓ 1 1* n/a n/a
8 Oncology ✓ ✓ 1* 1* n/a n/a
PPI patient and public involvement, TMG trial management group, TSC trial steering committee, n/a not applicable, − not observed
*Public contributors interviewed. Different public contributors were present at the TMG and the TSC of both trials 7 and 8 for a total of 7 public contributors
observed in meetings
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Table 3 Characteristics of interview participants
Participant ID Role Trial(s) involved in (subject area),
where applicable
01 TSC Chair 1, 2 (oncology)
02* Project lead 1, 5 (oncology)
03 TSC coordinator #1 1, 2 (oncology)
04 TSC coordinator #2 1, 2 (oncology)
05* Sponsor representative 1, 2 (oncology)
06* Sponsor representative 1, 2 (oncology)
07* Trial manager 1 (oncology)
08* CI 2 (oncology)
09* Trial manager 2 (oncology)
10* Trial manager 3 (arthritis)
11* Statistician 3 (arthritis)
12* Trial manager 3 (arthritis)
13 Statistician 3 (arthritis)
14 CI 3 (arthritis)
15 TSC Chair 3 (arthritis)
16* Trial manager 4 (frailty)
17 TSC Chair 4 (frailty)
18 CI 4 (frailty)
19 TMG Chair 4 (frailty)
20* TMG member 4 (frailty)
21* Trial manager 5 (oncology)
22 Statistician 5 (oncology)
23* CI 5 (oncology)
24* Independent TSC member 5 (oncology)
25 Independent TSC member 5 (oncology)
26* Trial manager 6 (urology)
27* Trial manager 6 (urology)
28* Statistician 6 (urology)
29* CI 6 (urology)
30* TSC Chair 6 (urology)
31* Independent TSC member 6 (urology)
32* TMG member 6 (urology)
33* Trial manager 7 (psychology)
34* CI 7 (psychology)
35* Public contributor 7 (psychology)
36* TSC Chair 7 (psychology)
37* Statistician 7 (psychology)
38* TSC Member 7 (psychology)
39 CTU Director 7 (psychology)
40* Trial manager 7 (psychology)
41* Trial manager 8 (oncology)
42* Chair 8 (oncology)
43a* Public contributor 8 (oncology)
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outcomes. With it being one of our primary out-
comes, it’s really important that we get the ques-
tionnaires back, and so if we can make that clearer
to patients up front, so that they know that the trial
involves a lot of questionnaires, then –
Public contributor, trial 8 TSC: Although you need
not to put too much stress on it…. it’s a balance…I
think you need to make them feel that any answer
is useful rather than just abandoning the whole
thing, yes.
In addition to this direct input into trial decisions,
public members also sought clarification and/or com-
mented on discussions related to data collection (trial 7
TMG and TSC, trial 8 TMG and TSC), protocol amend-
ments (trial 5 TMG, trial 8 TMG), recruitment (trial 8
TMG), retention (trial 7 TSC), data analysis (trial 8
TMG), trial progression (trial 8 TMG) and provided en-
couragement/positive feedback to trial team members
(trial 8 TSC).
Public contributor, trial 5 TMG: Can I just go back
on what you said, it would be introduced through
all arms of the trial?
CI, trial 5 TMG: Sorry that was me not speaking
clearly…I didn’t mean all arms, I meant all stages.
All public contributors interviewed described their in-
put to the improvement of the trial in some way, either
through shared decision-making during meetings, or
providing feedback on material behind the scenes.
…I did help to influence the decision, because my
actual inputs were taken in and were used, along
with everybody else’s. If you like, I completed the
equation. [35, public contributor, trial 7]
However, some interviewees described public contrib-
utors as passive, endorsing decisions made by the rest of
the committee.
…I don’t think they [public contributor] necessarily
were involved in making the decision…I think they
ratified our decisions rather than helped us make
them, if that makes sense? [36, TSC chair, trial 7]
This more passive PPI role was also observed at three
out of the six meetings where public members were
present (observation notes, trial 5 TMG, trial 6 TSC,
trial 7 TSC). Public contributors were not particularly
vocal during these meetings, nor were they encouraged
to express their views by other members of the trial
team.
Barriers and facilitators to meaningful PPI in trial
oversight
Interviewees reflected on challenges to engaging PPI in
trial oversight committees, as well as how to facilitate
more meaningful ongoing involvement of public contrib-
utors. This included confusion around the definition and
role of PPI, appreciated qualities of public contributors,
routes to invite public contributors, involving public
contributors at the optimal level of trial oversight and
trial stage, formality of oversight meetings and technical
language and support and/or mentorship from the trial
team.
Confusion about definition and roles of PPI
Some trialists expressed ignorance or confusion about
the active role that public contributors could play in trial
oversight committees. At trial 4’s TMG meeting, there
was uncertainty about which activities satisfied the label
of PPI from the funder’s perspective. The distinction be-
tween qualitative research, stakeholder engagement and
PPI activities was not well understood or delineated:
Table 3 Characteristics of interview participants (Continued)
Participant ID Role Trial(s) involved in (subject area),
where applicable
43b* Public contributor 8 (oncology)
44 Statistician 8 (oncology)
45* Sponsor representative 8 (oncology)
46* CI of other trial/member of TSCs n/a
47* Funder representative n/a
48 Sponsor representative n/a
49* Funder representative n/a
50* Statistician n/a
51* Funder representative n/a
CI Chief Investigator, CTU clinical trials unit, TMG trial management group, TSC trial steering committee
*Interviewee discussed PPI
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I think it’s perhaps recognising that tension between
something that is very overtly and officially PPI…
having lay members in your Trial Steering Commit-
tee or, “We had engagement with them when we
were putting in the bid … and we did get people to
look at the participant information sheets.”…but
whether we were counting things, or whether we
were saying it was the qualitative research element
in the intervention development is a bit grey. [19,
TMG Chair, trial 4 - TMG meeting]
Other trialists expressed a degree of reservation and scep-
ticism about PPI in trial oversight and concerns that PPI
could be tokenistic, motivated by funders’ requirements.
I agree it’s important, but the way it’s done at the
moment, I think it’s hit and miss and often it’s
tokenism, which is the worst of all worlds...I just
wish it wasn’t like the Emperor’s new clothes, that
people would have the courage to say “We don't
think we need PPI at the moment, but when we do,
we’ll get someone”…everybody at the moment
thinks it’s fashionable, it’s what happens…I think
there’s a great resource out there to get used, but
I’m not sure of the optimal way of doing it [28, Stat-
istician, trial 6]
Appreciated qualities of public contributors
The importance of selecting the “right” people to act as
public contributors in trial oversight was seen as critical
in moving towards an active PPI role.
…you need to find the right person because you
don’t want it to just be tokenism… [31, Independent
TSC member, trial 6]
However, selecting appropriate public contributors
was challenging; one participant described it as “the
biggest art form” [38, TSC member, trial 7]. Inter-
viewees felt that previous committee or group experi-
ence (e.g. patient groups, ethics or other research
committees) and an understanding of the research
process could be beneficial. Some participants, includ-
ing public contributors, felt that detailed knowledge
of the research process, trial methodology and tech-
nical language was needed to enable input in some
discussions.
…the issue I think we have with PPI is finding
knowledgeable people who have an interest and un-
derstanding of research…sometimes it’s more of a
hindrance because people don’t understand the
need for research or the research processes [26,
Trial manager, trial 6]
However, the value of “professionalised” public con-
tributors with research experience and skills, was con-
tested. While such detailed knowledge could be
helpful, these “expert” public contributors were also
perceived as potentially less representative of the
“average” patient voice. Some trialists felt public con-
tributors with a research and non-research back-
ground could keep a “healthy perspective about the
trial” [21, Trial manager, trial 5].
Some interviewees also reflected on instances when a
public contributor’s experience and/or organisational af-
filiations created a personal agenda or an “axe to grind”
[28, Statistician, trial 6], driving their desire to be in-
volved in trial oversight. In these instances, PPI was per-
ceived to be misguided and unhelpful in facilitating
effective trial oversight as these contributors were not
focused on the trial purpose or validity and discussions
were considered off task.
We had one example where…the patient represen-
tative was from the [national organisation]. They
have very definite opinions and beliefs about [topic],
and basically this representative just didn’t believe
the trial was necessary…So that was a bad experi-
ence. Where I don’t think that person was in any
way, shape or form, protecting the safety of the par-
ticipants…Nor was it protecting the integrity of the
trial. [37, Statistician, trial 7]
Conversely, the absence of a “personal agenda” to-
gether with direct experience of a relevant clinical condi-
tion was valued in public contributors.
Interviewer: How do you know she’s a good patient
advocate?
[42, Chair, trial 8]: firstly…a breadth of know-
ledge which comes across in the way she re-
sponds to comments and questions – sound
stuff…she’s sympathetic, empathetic and…very
well focused…Also…she has cared for somebody
who had [clinical condition], so there’s an inside
knowledge, a personal aspect to her as well which
she doesn’t let come through at the meetings.
There’s no personal agenda.
However, some trialists noted direct experience of a
disease or condition could at times make it difficult
for a public contributor to regularly attend meetings.
For example, in the event of relapse of a condition or
the physical limitations of an on-going condition.
Other participants reported that public contributors’
broader commitments could also impact on continued
involvement.
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The lay reps come on board early. They are enthusi-
astic. They then do not come to any more meet-
ings…I think that is an incredible shame, if they just
decide that it is not for them anymore, or they are
too busy, or if they are a lay rep because they have
got a condition, and they get ill. So I think, to me,
choosing the lay representatives is the biggest chal-
lenge. [38, TSC member, trial 7]
Routes to invite public contributors
The presence of more than one public contributor in
trial oversight committees was suggested to be helpful as
their shared experience could facilitate self-confidence in
their role, and hence contribution to the discussions.
Having two public contributors was also seen to help
with continuity, by increasing the likelihood that at least
one would be able to attend meetings.
Interviewer: …and you have two because...?
02, Project lead, trials 1,5: Because of continuity,
partly people can’t always turn up to meetings,
partly because when you’ve got a lot of high pow-
ered people around a table it can be difficult for
people to make their voices and opinions heard
and…two people there can in fact really help, partly
through if they do have a spell of ill health they
don’t feel obliged to make an effort to engage when
they don’t feel up to it…
Methods used by trialists to invite public contributors
to join oversight committees included contacts such as
friends or colleagues, existing networks or committees
and direct advertising. In some trials, these methods
were applied opportunistically whereas in others more
structured or formal efforts were made to invite public
contributors. Trialists did not offer views on the method
they thought most effective, rather they described exam-
ples of when their chosen process had proved effective
or not. In one trial, a public member had moved from
the iDMC to the TSC after the decision was taken that
the iDMC could stand down; this was viewed positively
as the contributor came with assumed levels of know-
ledge and understanding about the trial.
…she transferred from the iDMC…We had the pa-
tient representative, she had to stand down, and
then when the decision was taken, that the DMC
could stand down, she was a kind of gift-wrapped
transfer. [37, Statistician, trial 7]
The CI of another trial described how he had recruited
a public contributor opportunistically through another
institution’s PPI network; however, difficulties had arisen
due to the contributor’s ill health.
He [public contributor] was given to me by some-
body else. I said can you find me a lay person from
your pool of PPI people...it's another university
where they've got a very active and developed PPI
network…and they're [public contributor] currently
unwell actually. So that's a problem. [46, CI of other
trials/TSCs member]
Participants differed as to whether they felt advertising
was an appropriate way to engage effective public con-
tributors. One interviewee felt you would be likely to get
someone with a personal agenda, who would not neces-
sarily participate for the right reasons.
It’s actually quite hard to find them [public contrib-
utors] and if you advertise you tend to get people
with an agenda. They get involved because it's
something they want to have a go about…They're
not always there for good purposes... [29, CI, trial 6]
However, a trial manager described a positive experi-
ence advertising and obtaining a public contributor who
had previous experience through a relevant research net-
work, and this had been helpful.
…we asked for the help of the [research network]…
and they went through the involvement centre to
get expressions of interest from people who had…
done some involvement work previously…[public
contributor]’s good…been helpful. [33, Trial man-
ager, trial 7]
Involving PPI at optimal level of oversight and trial stage
Participants were asked on which oversight committee
they thought public contributors were best placed to
contribute. Some reported they did not have a strong
opinion either way and/or enough experience to judge
which level of oversight would be optimal. Most partici-
pants that did have a view felt that PPI was most rele-
vant at the TMG level where the details of a trial are
resolved, for example, patient information leaflets and
questionnaires.
I think probably TMG…the best place to get input
from them because that's really where we make de-
cisions about changes to questionnaires and things
like that... [29, CI, trial 6]
One senior trialist reflected in more depth on the ra-
tionale behind including PPI at the TMG and not the
TSC level; exposure to sensitive data and discussions
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that may take place at the TSC could impact adversely
on public contributors’ future contacts with patients
and/or clinicians. In addition, this participant felt that
the PPI patient advocate role could be problematic for
the TSC with its focus on “independent” monitoring and
oversight, which may preclude public contributors with
strongly held views about particular treatments.
…we decided the TSC…wasn’t quite the right place
to put patient representatives…it could cause prob-
lems for them, the trial, the patients we have are…
very often advocates for (the) treatment of the re-
search - we thought…the discussions that they have
with patients and doctors, they could find them-
selves in a more difficult position by having been
exposed to certain data and conversations and so
we thought the TMG is probably the right place...
[02, Project lead, trials 1,5]
PPI contributions at the TMG level were also thought
to be better due to the greater frequency of these meet-
ings, which could better facilitate the capacity of PPI to
impact on trial conduct. However, some trialists noted
that more meetings required a greater time commitment
from public contributors, which might influence their
ongoing engagement and involvement. The infrequency
of TSC meetings could also reduce the workload for
public contributors and help their engagement. For ex-
ample, in one trial, it was deemed more appropriate for
public contributors to join the TSC as it was felt the pa-
tient population were unlikely to cope with the heavy
workload and commitment of the TMG.
…because we look at people who are pretty old
and frail, it’s actually quite hard to do that…in
the TMG because that’s a group where you’re
asking quite a lot of people to come along to a
monthly meeting to read stuff, to really get very
immersed in the whole thing and to potentially
have to do stuff as well… [31, Independent TSC
member, trial 6]
There was also discussion about PPI that was car-
ried out separately to oversight meetings. As previ-
ously described for trial 4, there was confusion at the
TMG meeting about what “counted” as PPI. An inter-
viewee from the trial described leading a patient
group which met separately to TMGs, reviewed study
documentation and was planning to conduct training
for new researchers. She considered this to be the
PPI for the trial.
Interviewer: …as I was listening to you, I just
thought, “Well, gosh, isn’t that…PPI involvement?”
20, TMG member, trial 4: I don’t know. It’s a hor-
rible boundary, isn’t it?...I’m in charge of PPI. So,
we’ve got this PPI group and we meet in between
TMGs and they’ve been doing loads of work on all
the documentation and they’re going to do training,
when we get our new Research Associate…It just
feels like that’s the PPI.
Other participants felt the level of oversight was less
important than the stage of the research process and
from a funder’s perspective, the early stages of trial de-
sign and development of the grant application were cru-
cial stages for PPI to help ensure feasibility.
I don’t mind where they are really as long as they
have some role, preferably at the time when the trial
is being designed because I think it’s really import-
ant they have their input into the feasibility... [51,
Funder representative]
The formality of oversight meetings and technical language
Participants reported that the formality of oversight
meetings could hinder the engagement of public con-
tributors who may be unaware of implicit “rules of en-
gagement” in academic settings.
…the patient representative had some issues with
maintaining her attendance at the meetings...I sus-
pect that the strangeness of…being on a TSC, be-
cause it is a fairly unusual activity. I think we tend
to forget that, as experienced researchers. But it’s
got a lot of rules, it’s quite formal; it’s designed for
academics really, to give their opinions. I think she
found the whole process bewildering. [37, Statisti-
cian, trial 7]
Additionally, technical language and jargon used in
oversight meetings could affect public contributors’ un-
derstanding of topics discussed, and hence impact on
the extent of their contributions.
It’s okay for me now, but I didn’t actually ask
them when I first started because I was a little
shy…but that became embarrassing, because
they’d been talking about it so long, I didn’t like
to say, “Just a minute, what does that mean?”
[43b, public contributor, trial 8]
During two meetings observed, senior trialists checked
public members’ understanding of topics and provided
additional explanation to aid understanding (observation
notes, trial #5 TMG, trial #8 TSC). A trial sponsor sug-
gested that advance planning was needed to ensure that
statistical issues were presented in a way that was more
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accessible to committee members without statistical
expertise:
I think the issues that come up from an iDMC need
to be very, very clearly laid out in advance by the
relevant statisticians and framed in the way that a
savvy clinician or lay member… - and I think lay
people probably should be involved - the statistician
needs to set up the presentation in such a way that
it doesn’t take statistical skills to follow. [06, Spon-
sor representative, trials 1&2]
Support and/or mentorship from the trial team
Some interviewees discussed training and/or mentoring
of public contributors to facilitate their sense of inclu-
sion and contribution to meetings.
...we make sure that any patient representative has ad-
equate training at the beginning before joining so we
have training teleconferences and just taking them
through the protocol and what it means and the or-
ganisation of the TMG… [21, Trial manager, trial 5]
The public contributors interviewed valued support
they had received in the form of email or telephone con-
tact with team members. This informal, ad hoc support
mechanism, which allowed for PPI input outside of over-
sight meetings, was seen as important.
I read it [notes of meetings] as well. If I can’t under-
stand it, I email [trial manager] and say, “Look, I
can’t understand this. What is it we are trying to say
here? What is trying to be said?” [35, public con-
tributor, trial 7]
In some instances, concerted efforts were made by trial
team members to facilitate ongoing PPI outside of meet-
ings and build relationships with public contributors.
For example, contributors were encouraged to contact a
specific trial team member if they wanted to discuss any-
thing they were concerned about or did not fully under-
stand. The trial manager at one TMG meeting
mentioned a follow-up meeting with the public contrib-
utors to ensure clarity of discussions.
21, Trial manager, trial 5 TMG: [public contributor
1] and [public contributor 2] I am conscious that was
a quite full of items agenda. I would like to follow this
up with you, tomorrow or in the next couple of days,
in a separate teleconference or in e-mail, so that
everything is clear to both of you. Particularly [public
contributor 1] as you just joined the TMG.
Public member, trial 5 TMG: Yes, sounds fine.
One trial manager described how their trials unit had
a PPI support staff member:
…we’ve actually as a CTU changed our approach…
we’ve now got somebody to…act as PPI support…
who is employed by the CTU…they [public contrib-
utors] have somebody that they can go to, to ask
questions… [12, Trial manager, trial 3]
Some interviewees also described the importance of
the Chair in facilitating PPI contributions during meet-
ings, particularly for those public members who were
less confident at speaking up in meetings.
…I think you need to either select people who are
confident about speaking in those kind of circum-
stances or you need to have a TSC chair who will
drag views out of them to specifically ask them what
they think and for their contribution…really the
TSC chair needs to be specifically reminded that
they have to involve the public members. [50,
Statistician]
Conversely, in one TMG, a lot of cross-talking be-
tween members was observed, with the Chair seeming
less effective at running the meeting (observation notes,
trial 8 TMG). The public contributor who was inter-
viewed subsequently commented that the PPI update at
the TMG was completely overlooked and that timekeep-
ing was an ongoing issue:
I felt…the meeting was a bit…lop-sided. We went
through the last agenda items as if they weren’t
there, including the patient representative’s report…
[Chair] didn’t even mention it...But, the time was
pressing and…[Chair] didn’t quite keep to time. But,
that’s been a general feature of those TMGs…some-
times, it’s gone on for much longer than two hours.
[43b, public contributor, trial 8]
Influence of PPI on study results
MEP and GT commented on the rigour of the research
and the credibility of the results, commenting that many
of the findings were similar to their own experiences in
trial oversight committees, and also made suggestions to
improve clarity of the results.
Discussion
To our knowledge, this is the first multi-method qualita-
tive study to investigate PPI activity within trial oversight
committees. Data were collected from observations of
TSC and TMG meetings across eight clinical trials fa-
cing challenges, and interviews with key stakeholders in-
cluding a wide range of trial staff, and public
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contributors. PPI was generally regarded as beneficial to
trials, providing the patient voice and/or playing a pa-
tient advocacy role. Examples of active and valued PPI
input were identified; however, not all trials had current
public contributors. Concerns around tokenism were
raised, as well as confusion about PPI. We describe facil-
itators to maximise meaningful PPI input in trial over-
sight. These include the need for careful consideration
and planning on how to recruit public contributors, the
optimal level of trial oversight and/or trial stage(s) to in-
volve public contributors and their ongoing support/
mentoring needs.
Our study found that public contributors were not al-
ways active in meetings observed. Taken at face value,
this may lead us to believe that the public contributor
had no impact on trial decisions; however, Crocker et al.
reported that this “passive presence” type of public con-
tributor could still impact the way professionals think
simply by being present at research meetings [27]. Our
findings demonstrate uncertainty as to how to undertake
PPI effectively with tokenistic PPI raised as a concern.
Previous research has identified tokenistic PPI as a prob-
lem in clinical trials and other studies, where it has been
described as a “self-fulfilling prophecy” or a “self-per-
petuating cycle” [5, 19–21, 23, 24]. A lack of clarity or
understanding about PPI leads to it being carried out in
a tokenistic way that allows for little impact on the re-
search. Researchers thus conclude that PPI has little
value and the cycle continues [5, 23]. Some trial com-
mittee members interviewed expressed rather counter-
productive views about public members, for example,
suggesting that public contributors may not make much
of an effort when they are ill. For PPI to have a meaning-
ful role in trial oversight, all trial team members need to
develop a shared view of the nature and role of PPI. This
includes an emphasis on co-production with a shift to-
wards a more equal relationship of power between public
contributors and other trial team members, which may be
uncomfortable for some researchers [37, 38].
We found that using technical language during meet-
ings could exclude public contributors, as has been re-
ported in other studies [4, 21, 24, 28, 39]. Participants
highlighted the need to present and discuss complicated
technical matters (such as statistics) in a more “lay” and
engaging way during oversight meetings. Interviewees in
our study also described the need for good chairing skills
to ensure all voices are heard in meetings, including
public members. The importance of the Chair in ensur-
ing patient understanding and inclusion at research
meetings has also recently been highlighted in the Can-
cer Research UK PPI toolkit [40]. Practical guidance for
Chairs of research meetings is available and highlights
the importance of developing relationships with public
members and fostering regular communication between
meetings [41]. Similarly, participants in our study de-
scribed how support and/or mentorship for public con-
tributors could facilitate contributors’ input and sense of
inclusion within oversight meetings. This included in-
duction meetings to explain the trial protocol and PPI
roles and regular communication and support between
oversight meetings to clarify issues. Previous studies
have also reported the benefit of informal and ad hoc
support provided by the research team [4, 5, 24, 28, 39],
and Bagley et al. have developed resources for providing
clear information about trial oversight to public mem-
bers including their role [16].
Interviewees also described uncertainty in how to go
about selecting public contributors, with one describing
it as an “art form”. The importance of finding the “right”
public contributors has been highlighted, with valued
characteristics reported to include enthusiasm, confi-
dence, impartiality and an interest in and understanding
of research [4, 28, 39]. However, we also identified con-
cerns that “professionalised” public members, with previ-
ous research and/or committee experience, may not
represent the “average” person within the relevant popu-
lation. These “professionalised” members may be more
likely to be selected by researchers for public roles as
they fit more easily into academic processes, which bet-
ter suit researchers’ agendas [39, 42]. Staley, however, as-
serts that public contributors do not lose their lay status
by virtue of their involvement in research [43]. She ar-
gues that certain aspects of a research project may bene-
fit from the perspectives of public contributors with
more research experience (e.g. the technical aspects of
trial design), whereas contributors without this experi-
ence may be ideally suited to other aspects (e.g. perspec-
tives on recruitment and patient-facing materials). It is
important that there is clarity about roles and responsi-
bilities of public contributors, including adequate sup-
port tailored to each role [44–46].
Rather than focusing on finding public members who
are “representative”, INVOLVE recommends seeking
people with the range of perspectives needed to inform
the research, as a few public members can never be rep-
resentative of the entire population of interest [44, 47].
Interviewees in our study recommended the inclusion of
experienced and less experienced public members to
provide a mix of skills and experience, help to build con-
fidence in public members and help with continuity,
similar to findings from the EPIC study, and as recom-
mended by INVOLVE [39, 44]. A recent qualitative
study investigating PPI in surgical trials reported that a
“two-tier” PPI model whereby a larger panel of public
contributors are consulted intermittently, with one or
two of the contributors more regularly involved with the
trial team, could lead to better representation and en-
gagement [22]. Our study also found that there is no
Coulman et al. Trials          (2020) 21:543 Page 11 of 15
one best avenue to recruit public contributors; this de-
pends on the trial and patient population, and adequate
consideration should be given to this at trial design stage
[44]. Improving diversity of PPI is also reflected in the
NIHR National Standards for PPI in research [48].
Our finding that public contributors may be best
placed in a TMG rather than solely a TSC supports find-
ings from the EPIC study [5]; however, our findings
highlight that this is dependent partially on the trial.
EPIC found that interviewees from trials which included
PPI solely on their TSCs (with no other PPI input) were
less likely to report impactful PPI, with TMG involve-
ment and other forms of more responsive PPI reported
to foster more meaningful involvement [5]. One trialist
in our study felt the TSC was more appropriate for PPI
due to the study population being unlikely to cope with
the greater frequency of TMG meetings. However, the
actual level of PPI within this trial is uncertain; the pub-
lic contributor was not observed to be particularly active
during the TSC meeting, and trialists from this trial
expressed reservations about tokenistic PPI. Previous re-
search supports the need to adapt PPI to the emergent
needs of a trial in order to facilitate more impactful PPI
[5, 20, 28]. For some trials and patient populations, more
“responsive”, flexible modes of PPI may be more appro-
priate, for example holding separate PPI meetings at
times and locations accessible to public contributors,
and/or seeking PPI on an “as needed” basis, rather than
viewing oversight meetings as the only format for PPI [5,
28]. Early PPI at trial design stage was raised as espe-
cially important from the perspective of funders in our
study and has been reported to be associated with
greater PPI impact in trials [5, 20, 21, 28].
A key strength of this study is that non-participant ob-
servation of oversight meetings was combined with in-
terviews with key stakeholders in ongoing trials to gain a
greater understanding of how PPI actually functions in
trial oversight. This allowed an in-depth exploration
from different perspectives that would not have been
possible using either method alone. Our observational
Table 4 Recommendations: Enhancing patient and public involvement in trial oversight
Steps to maximise the benefit of PPI Facilitated by:
Agree PPI needs of trial with research team (early trial design stage)*
• Define clear role/s and/or goals for PPI
• Define trial stages that PPI needed – including trial design stage
• Define demographic characteristics, skills and experience desired
from public contributors
• Identify optimal format for PPI (e.g. attendance at trial oversight
committee(s), and/or separate PPI meetings, email/telephone) –
negotiate this with public contributors recruited
• Ensure PPI is costed properly to re-imburse for public
contributors’ time and expenses, including carer support
if appropriate
• Ensure PPI plan is fully justified in both funding
applications and trial protocols
• Training for research team on the role PPI can play in trials and how
to maximise meaningful input. Include opportunities for discussion.
• Accessing useful PPI planning resources (e.g. PPI Toolkit for clinical
trials [16]), and the NIHR INVOLVE public involvement cost calculator
(https://www.invo.org.uk/resource-centre/payment-and-recognition-
for-public-involvement/involvement-cost-calculator/)
• Consulting with existing patient or public panels may be useful at
this early stage to help define PPI needs
• Consider inviting public contributors to be co-applicants on grant
applications
Recruit diverse public contributors
• Consider effective routes to invite public contributors
(e.g. local groups, national organisations, existing PPI
groups, advertising) to allow for diversity
• Recruit more than one public contributor, focusing on
diversity of characteristics, skills and experience
(e.g. some with research/committee experience and
some without)
• Drawing on insight of colleagues with previous experience of
identifying and working with public contributors from target
population, and existing relevant patient or public panels.
Engage public contributors in trial oversight
• Provide an induction to the trial for public contributors
including oversight processes
• Ensure meeting Chairs have skills to engage public
contributors
• Provide on-going mentoring/support to public
contributors in between oversight meetings,
e.g. regular meetings/phone calls to foster
relationship, answer queries, and provide
training as deemed appropriate
• Accommodate needs of the patient group to
facilitate PPI attendance at meetings (e.g. shorter
meetings/attendance for part of the meeting,
care needs or caring responsibilities)
• Adapt format of PPI to the emerging needs
of the trial and public contributors
• Accessing PPI training/support for trial team including meeting Chairs
(e.g. UKCRC/NCRI PPI in research groups - Guidance for Chairs [41])
• Identifying appropriate research team member to provide on-
going support to public contributors, and allowing protected
time for this within their role
• Drawing on relevant resources provided in the PPI Toolkit for
clinical trials [16] to familiarise public contributors with their
role in the trial oversight committee, academic terminology
and environment
• Considering both academic and public contributors’ commitments
PPI patient and public involvement
*Relevant patients or lay members of the public should be involved in defining the PPI needs for a trial
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data revealed how public contributors varied in their in-
puts into discussions at oversight meetings and the role
of the Chair in facilitating public contributions. A limita-
tion of this study is that these eight trials are not repre-
sentative of all late-phase randomised trials—all were
UK-based and publicly-funded. Trials conducted in
other countries, with other funders and alternative over-
sight structures, may experience different issues. Add-
itionally, only trials undergoing challenges were
included. Whether PPI functions differently in trials that
are undergoing challenges compared with those that are
not merits further research. The selection of trials
undergoing challenges ensured that these oversight
meetings were critical to trial progress, so it was notable
that public contributors were present at only six of the
14 observed meetings. At two additional meetings (one
TMG, one TSC) public contributors were invited but
not in attendance. This study focused on the role and
function of trial oversight committees in general rather
than PPI specifically; however, this could also be seen as
a strength as it may have reduced the likelihood of “so-
cial desirability” issues as identified by one interviewee
in describing PPI as “the emperor’s new clothes”. Public
contributors were not involved in the design of this
study; however, they provided a valuable perspective,
commenting on the integrity of the results and helping
to shape the recommendations in this paper. Although
only three public contributors were interviewed, all in-
terviewees approached agreed to be interviewed. How-
ever, the majority of interviewees discussed PPI and we
were able to observe seven public contributors ‘in action’
during meetings. Future research would benefit from a
larger number of interviews with public members to en-
able a more in-depth comparison of their perspectives
with other trial team members.
Based on our study and previous literature, we provide
practical suggestions on how to maximise meaningful
PPI input in trial oversight (Table 4).
These include providing support and/or training for the
trial team in how to undertake PPI effectively (including
how to support and engage public contributors during
and in-between oversight meetings), early planning to es-
tablish clear goals and plans for PPI within a trial, adapt-
ing oversight processes to facilitate effective PPI
(especially PPI by “non-professional” members), adjusting
the format of PPI to the emerging needs of the trial and
regular support for public contributors from the trial
team. Our findings highlight the need for further re-
search into how to adapt PPI to the needs of individ-
ual trials, rather than adopting a prescriptive model,
and this was recently prioritised as a key area for re-
search from a Delphi survey of PPI stakeholders [20].
Future research should also seek to develop methods
to improve the inclusion of “non-professional” public
contributors within trials and to evaluate the impact
of PPI training/support for both trialists and public
contributors.
Conclusions
To facilitate more meaningful PPI within clinical trials,
it is essential that that PPI planning happens at early
trial design stage. This includes consideration of how to
recruit and involve public contributors within trial over-
sight, as well as support and mentorship for both public
contributors and trialists in how to engage with PPI effect-
ively to maximise trial benefit. Relevant patients and/or
members of the public should be involved in the planning
process, and trial teams may wish to consider engaging
existing patient or public panels to facilitate this.
Influence of PPI on study discussion and conclusions
Public contributors (MEP and GT) provided valuable
feedback on topics that should be brought out more
strongly in the Discussion, Conclusions and the recom-
mendations provided in Table 4, as well as suggestions to
improve the clarity of the recommendations presented.
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